Cancer immunoprevention: from mice to early clinical trials
Abstract Cancer immunoprevention is based on the fact that a functioning immune system controls tumor onset and development in humans and animals, thus leading to the idea that the enhancement of immune responses in healthy individuals could effectively reduce cancer risk later in life. Successful p...
Main Authors: | Arianna Palladini, Lorena Landuzzi, Pier-Luigi Lollini, Patrizia Nanni |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-06-01
|
Series: | BMC Immunology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12865-018-0253-0 |
Similar Items
-
OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis
by: Patrizia Nanni, et al.
Published: (2018-08-01) -
The Promise of Preventive Cancer Vaccines
by: Pier-Luigi Lollini, et al.
Published: (2015-06-01) -
Preclinical HER-2 vaccines: from rodent to human HER-2
by: Pier-Luigi eLollini, et al.
Published: (2013-06-01) -
Targeted Vaccination against Human α-Lactalbumin for Immunotherapy and Primary Immunoprevention of Triple Negative Breast Cancer
by: Vincent K. Tuohy, et al.
Published: (2016-06-01) -
Cancer Immunoprevention and Public Health
by: Sandeep K. Singh, et al.
Published: (2017-05-01)